Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NxStage clears US hurdle in Medisystems acquisition:

This article was originally published in Clinica

Executive Summary

US antitrust authorities have completed a review of NxStage Medical's proposed buyout of its long-term business partner Medisystems Corporation, bringing NxStage closer to purchasing the developer of disposables used in dialysis and blood treatment. The firm says it has begun to implement organisational changes in anticipation of the transaction, expected to close during the fourth quarter of 2007. Lawrence, Massachusetts-based NxStage has promoted that Michael Webb to the newly-created position of senior vice-president of quality, regulatory and clinical affairs, whereas, upon the closing of the deal, Phil Licari will resign as senior vice-president and chief operating officer to pursue other opportunities. The deal, signed in June, is valued at around $78.7m (see Clinica No 1259, p 18).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel